Streetbeat News

ICCM

IceCure Medical Ltd

Industry

Medical - Devices

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Open

1.38

Mkt cap

80M

Volume

166K

High

1.44

P/E Ratio

-5.07

52-wk high

1.66

Low

1.38

Div yield

N/A

52-wk low

0.48

IceCure Medical Ltd. (NASDAQ:ICCM) announced that its ProSense® System, a minimally-invasive cryoablation technology for tumor destruction, has received updated regulatory approval from the Central Drugs Standard Control Organization in India. This approval is in line with new regulations and adds to existing approvals for various surgical and oncological uses. ProSense® is distributed in India by Novomed and was first used for breast cancer cryoablation in June 2023. IceCure presented ProSense® at the Breast Imaging Society of India's conference, indicating a focus on expanding its market presence in India.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:12 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 11:31 am

U.S. stocks saw gains with the Dow Jones rising by 0.27%, NASDAQ by 0.12%, and S&P 500 by 0.07%. Consumer discretionary shares led the gains, while health care shares declined. Crude oil surged by 2.1%, and gold also rose. Carbon Revolution, PDD Holdings, and IceCure Medical saw significant stock price increases following positive news. Tharimmune's shares plummeted after pricing a public offering at $1 per share. SenesTech and Cabaletta Bio also experienced sharp declines in their share prices.

Portfolio Pulse from Lisa Levin

November 28, 2023 | 7:57 pm

SenesTech, Inc. (NASDAQ:SNES) shares plummeted by approximately 50% after announcing the pricing of a $5.0 million public offering at $1.30 per share with additional warrants. The stock dropped to $0.9189. Other stocks experienced significant movements, with gainers including IceCure Medical Ltd (ICCM), RedHill Biopharma Ltd. (RDHL), and HNR Acquisition Corp (HNRA), among others. Losers included Tharimmune, Inc. (THAR), Cabaletta Bio, Inc. (CABA), and Acelyrin, Inc. (SLRN), with Tharimmune's shares falling sharply after pricing its public offering at $1 per share.

Portfolio Pulse from Lisa Levin

November 28, 2023 | 7:44 pm

IceCure Medical Ltd. (NASDAQ:ICCM) stock is trading higher after an independent study showed its IceCure system has a 100% local control rate for re-treating initially resistant tumors. The study also noted a high patient discharge rate post-cryoblation and preservation of renal function. CEO Eyal Shamir compared the findings to their ongoing ICESECRET study. ICCM's trading volume surged following the news, with shares up 49%.

Portfolio Pulse from Erica Kollmann

November 28, 2023 | 3:18 pm

IceCure Medical's stock is trading higher following the announcement of a new study published in peer-reviewed journals, which demonstrates the safety and efficacy of its ProSense system.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 3:14 pm

IceCure Medical announced the release of a study published in 'Cancers' showing the safety and efficacy of ProSense with a 92% disease-free survival rate at a median follow-up of 26.5 months. Avidity Biosciences has partnered with Bristol Myers Squibb in a $2.3 billion deal for cardiovascular RNA therapeutics, receiving $100 million upfront. SMX shares surged 50% premarket after announcing the planned launch of the world's first Plastic Cycle Token.

Portfolio Pulse from ryanfaloona@benzinga.com

November 28, 2023 | 1:45 pm

IceCure Medical announced the publication of a study in 'Cancers' showing the safety and efficacy of its ProSense system. The study reported a 92% disease-free survival rate at a median follow-up of 26.5 months.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:06 pm

IceCure Medical Ltd. has filed an appeal with the FDA for a review of its De Novo Classification Request for ProSense, a cryoablation technology for treating early-stage breast cancer, after the initial denial.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 12:36 pm

IceCure Medical has received a Nasdaq minimum bid price notification. This means that the company's stock has not met the minimum bid price of $1.00 per share for 30 consecutive business days.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.